CRNX Crinetics Pharmaceuticals, Inc. - Common Stock
$84,77
Harga · Agu 19, 2026
Fundamental per Agu 3, 2026
Rentang 52M
$29–$85
100% of range
Peringkat Analis
HOLD
21 analysts
Target Harga
$86
+1% upside
P/E (TTM)
-17.1
ROE
-43.0%
Margin Laba Bersih
-6046.2%
Tentang Crinetics Pharmaceuticals, Inc. - Common Stock Tinjauan perusahaan dari Wikipedia
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
Baca selengkapnya
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
In July 2026, Vertex Pharmaceuticals agreed to acquire the company for $10 billion.
History
Struthers, Zhu, Kusnetzow, and Betz founded Crinetics in 2008 after previously working together on a small molecule drug for the treatment of endometriosis at Neurocrine Biosciences.
Crinetics expanded into a larger laboratory in 2010. After receiving NIH grant funding, Crinetics moved into its second laboratory.
In 2011, Crinetics Pharmaceuticals competed for the Michelson Prize, a competition sponsored by the Found Animals Foundation to develop a low-cost, non-surgical method for sterilizing dogs and cats, which would later lead to the licensing of a molecule for the treatment of acromegaly in large breed dogs.
Crinetics first synthesized its lead drug candidate to treat acromegaly. The drug was named paltusotine, in 2016. Crinetics Pharmaceuticals went public with an IPO in 2018. It conducted Phase II trials for paltusotine from 2019 to 2020. It conducted Phase III trials for paltusotine from 2021 to 2024. After the drug succeeded in a second Phase III study, the FDA accepted the company's new drug application for paltusotine and the company announced it was planning for a 2025 launch for the drug. The FDA set a Prescription Drug User Fee Act for the drug on September 25, 2025.
In 2021, Crinetics, together with 5AM Ventures and Frazier Healthcare Partners, formed an independently operated new company, Radionetics Oncology, aimed to develop a deep pipeline of novel, targeted, nonpeptide radiopharmaceuticals for the treatment of a broad range of oncology indications.
Crinetics partnered with the veterinary medicine company Loyal to develop a pill to extend the lifespans of large dogs in 2023.
In 2024, Scott Struthers received the Ernst & Young Entrepreneur of the Year Award for his work with Crinetics. In 2024, Crinetics was reported to have patent activity in rare diseases, health technology, and addiction therapies.
In 2024, Radionetics formed a strategic relationship with Eli Lilly and Company to take forward Radionetics’ proprietary GPCR targeting small molecule radiopharmaceuticals. Under the terms of the agreement, Radionetics received a $140 million upfront cash payment. As part of the strategic agreement, Lilly obtained the exclusive right to acquire Radionetics upon conclusion of an exercise period for $1 billion.
Crinetics also established its first office outside the United States in Zug, Switzerland in 2024.
In 2025, Crinetics Pharmaceuticals plans to file an Investigational New Drug for an oral thyroid stimulating hormone receptor antagonist and its nonpeptide drug conjugate (CRN09682). A total of four development candidates are currently in IND-enabling studies, including a PTH antagonist (Hyperparathyrodism), non-peptide drug conjugate (NETs and SST2-expressing solid tumors), TSH antagonist (Graves’ disease & TED) and SST3 agonist (ADPKD).
In July 2026, Vertex Pharmaceuticals agreed to acquire Crinetics for $10 billion.
Treatments
Crinetics’ pipeline focuses on synthesizing novel molecules for rare endocrine diseases. It is most known for developing paltusotine, a drug designed to treat the hormonal disorder acromegaly. Paltusotine works by helping moderate elevated IGF-1 levels, which is the main symptom of acromegaly. Paltusotine has also been tested as a treatment for carcinoid syndrome.
Crinetics has also developed oral treatments for neuroendocrine tumors, hyperinsulism, and Cushing's disease. The company's drug for treating Cushing's disease, Atumeltnant (also known as CRN049894), works by reducing levels of ACTH.
The company's pipeline also includes an oral parathyroid hormone inhibitor program for hyperparathyroidism and treatments for thyroid eye disease, Graves' disease, and obesity. Additionally, Crinetics nonpeptide drug conjugates (NDCs) include CRN09682, which is a somatostatin receptor 2 (SST2) targeted drug. NDCs are a new technology developed in-house by Crinetics.
== References ==
Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗
CRNX Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
Harga
$84.77
Kapitalisasi Pasar
$8.10B
P/E (TTM)
-17.1
EPS (TTM)
$-4.95
Pendapatan (TTM)
$8M
Imbal Hasil Dividen
—
ROE
-43.0%
D/E Utang/Ekuitas
—
Rentang 52M
$29 – $85
CRNX Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
Configure
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Pendapatan & Laba Bersih
$8M
2016-12-31
→
2025-12-31
EPS
$-4.95
2020-12-31
→
2025-12-31
Arus Kas Bebas
$-384M
2018-12-31
→
2025-12-31
Margin
-6046.2%
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
Metrik
Tren 5 Tahun
CRNX
Median Rekan
P/E (TTM)
-17.1
47.9
P/S (TTM)
1052.7
16.2
P/B
8.2
9.3
Price / FCF (Harga / FCF)
-21.1
—
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
Metrik
Tren 5 Tahun
CRNX
Median Rekan
Operating Margin (Margin Operasi)
-6714.8%
—
Net Profit Margin (Margin Laba Bersih)
-6046.2%
5.1%
ROA
-36.3%
0.81%
ROE
-43.0%
-15.3%
ROIC
-52.1%
—
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
Metrik
Tren 5 Tahun
CRNX
Median Rekan
Current Ratio (Rasio Lancar)
12.3
2.7
Quick Ratio (Rasio Cepat)
12.1
—
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
Metrik
Tren 5 Tahun
CRNX
Median Rekan
Revenue YoY (Pendapatan YoY)
640.7%
—
Revenue CAGR 3Y (CAGR Pendapatan 3T)
17.6%
—
Revenue CAGR 5Y (CAGR Pendapatan 5T)
155.3%
—
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
Metrik
Tren 5 Tahun
CRNX
Median Rekan
CRNX Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
TAHAN
21 analis
- Beli Kuat 3 14,3%
- Beli 4 19,0%
- Tahan 14 66,7%
- Jual 0 0,0%
- Jual Kuat 0 0,0%
Target Harga 12 Bulan
10 analis · 2026-08-13
Median
$85.00
Rata-rata
$85.50
← Di bawah semua target
$84.77
Rendah
$85.00
Tinggi
$90.00
Target median
$85.00
+0,3%
Target rata-rata
$85.50
+0,9%
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
Kejutan Rata-rata
-0.01%
| Periode | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|
| 30 Juni 2026 | $-1.14 | $-1.23 | 0.09% |
| 31 Maret 2026 | $-1.23 | $-1.26 | 0.03% |
| 31 Des. 2025 | $-1.29 | $-1.39 | 0.10% |
| 30 Sep. 2025 | $-1.38 | $-1.28 | -0.10% |
| 30 Juni 2025 | $-1.23 | $-1.12 | -0.11% |
| 31 Maret 2025 | $-1.04 | $-0.96 | -0.08% |
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| CRNX | $4.45B | -9.4 | 640.7% | -6046.2% | -43.0% | — |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | — |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
| AXSM | $9.29B | -49.6 | 65.5% | -28.7% | -227.0% | — |
| LQDA | $3.01B | -43.1 | 1031.2% | -43.5% | -230.0% | — |
| BLTE | — | — | — | — | — | — |
| DFTX | $1.32B | -6.5 | 212.0% | — | -71.0% | — |
| AMRX | — | 57.3 | 8.1% | 2.4% | -80.0% | 36.9% |
| LGND | $3.74B | 30.8 | 60.4% | 46.4% | 13.5% | — |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi 17
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | $1M | $4M | $5M | $1M | $71.0K | $1M | $2M | $2M | |
| Cost of Revenue | $1M | $0 | $0 | · | · | · | · | · | · | |
| R&D Expense | $332M | $240M | $169M | $130M | $84M | $57M | $42M | $24M | $9M | |
| SG&A Expense | $191M | $100M | $58M | $42M | $25M | $18M | $14M | $7M | $2M | |
| Operating Expenses | $524M | $340M | $227M | $173M | $109M | $75M | $55M | $31M | $11M | |
| Operating Income | $-517M | $-339M | $-223M | $-168M | $-108M | $-75M | $-54M | $-29M | $-9M | |
| Interest Expense | · | · | · | · | · | · | · | · | $8.0K | |
| Interest Income | $52M | $41M | $13M | $4M | $157.0K | $991.0K | $3M | $2M | $26.0K | |
| Other Non-op | $-357.0K | $-519.0K | $-159.0K | $5M | $61.0K | $1M | $3M | $2M | $-30.0K | |
| Pretax Income | $-465M | $-298M | $-209M | $-164M | $-108M | $-74M | $-50M | $-27M | $-9M | |
| Income Tax | $180.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-465M | $-298M | $-215M | $-164M | $-108M | $-74M | $-50M | $-27M | $-9M | |
| EPS (Basic) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 | · | · | · | |
| EPS (Diluted) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 | · | · | · | |
| Shares (Basic) | 94,057,000 | 80,783,000 | 58,071,000 | 51,982,000 | 38,436,000 | 30,448,000 | · | · | · | |
| Shares (Diluted) | 94,057,000 | 80,783,000 | 58,071,000 | 51,982,000 | 38,436,000 | 30,448,000 | · | · | · | |
| EBITDA | $-513M | $-339M | $-223M | $-168M | $-108M | $-75M | $-54M | $-29M | · |
Neraca 24
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $102M | $265M | $55M | $33M | $201M | $93M | $40M | $45M | $14M | |
| Short-term Investments | $926M | $1.09B | $504M | $302M | $133M | $78M | $78M | $119M | · | |
| Receivables | $592.0K | $0 | · | · | · | · | · | · | · | |
| Inventory | $2M | $0 | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $21M | $16M | $11M | $11M | $7M | $5M | $3M | $973.0K | |
| Other Current Assets | $3M | $2M | $448.0K | $2M | $912.0K | $1M | $668.0K | $876.0K | $239.0K | |
| Current Assets | $1.05B | $1.38B | $574M | $345M | $345M | $177M | $123M | $167M | $15M | |
| PP&E (Net) | $14M | $12M | $11M | $4M | $3M | $3M | $4M | $4M | $400.0K | |
| PP&E (Gross) | $22M | $20M | $16M | $8M | $6M | $6M | $6M | $5M | $704.0K | |
| Accum. Depreciation | $8M | $8M | $5M | $4M | $3M | $3M | $2M | $741.0K | $304.0K | |
| Other Non-current Assets | · | $3M | $2M | $37.0K | $0 | $40.0K | $82.0K | · | $33.0K | |
| Total Assets | $1.13B | $1.43B | $635M | $352M | $351M | $183M | $130M | $171M | $16M | |
| Accounts Payable | $23M | $6M | $7M | $7M | $3M | $6M | $5M | $5M | $403.0K | |
| Accrued Liabilities | · | · | · | · | · | · | · | $4M | $179.0K | |
| Current Liabilities | $85M | $60M | $44M | $28M | $16M | $10M | $8M | $8M | $897.0K | |
| Capital Leases | $42M | $45M | $48M | $2M | $3M | $4M | $5M | · | · | |
| Other Non-current Liabilities | $3M | $829.0K | $0 | · | · | · | · | · | · | |
| Total Liabilities | $134M | $110M | $96M | $36M | $19M | $15M | $13M | $11M | $920.0K | |
| Common Stock | · | · | $253.0K | $0 | · | · | · | $24.0K | $1.0K | |
| Retained Earnings | $-1.42B | $-952M | $-654M | $-439M | $-275M | $-168M | $-94M | $-43M | $-16M | |
| AOCI | $2M | $963.0K | $977.0K | $-4M | $-382.0K | $25.0K | $148.0K | $61.0K | · | |
| Stockholders' Equity | $992M | $1.32B | $539M | $316M | $332M | $169M | $117M | $160M | $-15M | |
| Liabilities + Equity | $1.13B | $1.43B | $635M | $352M | $351M | $183M | $130M | $171M | $16M | |
| Shares Outstanding | 95,575,000 | 92,926,000 | 68,175,000 | 53,877,000 | 47,597,000 | 33,001,000 | 24,263,000 | 24,061 | 1,549,575 |
Arus Kas 13
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $1M | $983.0K | $922.0K | $948.0K | $887.0K | $471.0K | $128.0K | |
| Stock-based Comp | $91M | $69M | $41M | $28M | $17M | $10M | $6M | $2M | $271.0K | |
| Deferred Tax | $0 | $0 | $0 | · | · | · | · | · | · | |
| Other Non-cash | $-8M | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-378M | $-230M | $-169M | $-115M | $-89M | $-62M | $-46M | $-19M | $-9M | |
| CapEx | $6M | $4M | $5M | $2M | $436.0K | $186.0K | $492.0K | $1M | $304.0K | |
| Investing Cash Flow | $174M | $-575M | $-200M | $-174M | $-56M | $217.0K | $42M | $-119M | $-304.0K | |
| Stock Issued | $0 | $985M | $370M | $117M | $250M | $114M | · | $106M | · | |
| Net Stock Activity | $0 | $970M | $369M | $117M | $250M | $114M | · | · | · | |
| Financing Cash Flow | $41M | $1.01B | $391M | $122M | $253M | $115M | $67.0K | $170M | $12M | |
| Net Change in Cash | · | $210M | $22M | $-167M | $108M | $53M | $-5M | $31M | $2M | |
| Taxes Paid | $89.0K | $0 | $0 | · | · | · | · | · | · | |
| Free Cash Flow | $-384M | $-230M | $-171M | $-117M | $-89M | $-62M | $-47M | $-21M | · |
Profitabilitas 7
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | · | |
| Net Margin | -6046.2% | -28720.7% | -5345.9% | -3460.4% | -9985.2% | -103960.6% | -4226.5% | -1116.8% | · | |
| Pretax Margin | -6043.9% | -28720.7% | -5345.9% | -3460.4% | -9985.2% | -103960.6% | -4226.5% | -1116.8% | · | |
| EBITDA Margin | -6664.1% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | · | |
| ROA | -36.3% | -28.8% | -43.5% | -46.6% | -40.3% | -47.0% | -33.4% | -29.0% | · | |
| ROE | -43.0% | -27.7% | -39.5% | -49.1% | -41.0% | -41.4% | -40.9% | -16.6% | · | |
| ROIC | -52.1% | -25.6% | -41.3% | -53.1% | -32.5% | -44.4% | -46.0% | -17.9% | · |
Likuiditas & Solvabilitas 2
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.3 | 23.0 | 13.1 | 12.5 | 21.6 | 16.9 | 14.8 | 21.0 | · | |
| Quick Ratio | 12.1 | 22.7 | 12.7 | 12.1 | 20.9 | 16.3 | 14.2 | 20.7 | · |
Efisiensi 3
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | |
| Inventory Turnover | 1.1 | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 26.0 | · | · | · | · | · | · | · | · |
Tingkat Pertumbuhan 3
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 640.7% | -74.1% | -15.3% | 339.4% | 1418.3% | · | · | · | · | |
| Revenue CAGR 3Y | 17.6% | -1.2% | 283.8% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 155.3% | · | · | · | · | · | · | · | · |
Valuasi (TTM) 10
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $8M | $1M | $4M | $5M | $1M | $71.0K | $1M | $2M | · | |
| Net Income TTM | $-465M | $-298M | $-215M | $-164M | $-108M | $-74M | $-50M | $-27M | · | |
| Market Cap | $4.45B | $4.75B | $2.43B | $986M | $1.35B | $466M | $608.8K | $722M | · | |
| P/E | -9.4 | -13.9 | -9.6 | -5.8 | -10.1 | -5.8 | · | · | · | |
| P/S | 578.1 | 4573.0 | 604.5 | 208.1 | 1254.4 | 6558.4 | 0.5 | 297.2 | · | |
| P/B | 4.5 | 3.6 | 4.5 | 3.1 | 4.1 | 2.8 | 0.0 | 4.5 | · | |
| P / Tangible Book | 4.5 | 3.6 | 4.5 | 3.1 | 4.1 | 2.8 | · | · | · | |
| P / Cash Flow | -11.8 | -21.0 | -14.6 | -8.6 | -15.3 | -7.5 | -0.0 | -37.1 | · | |
| P / FCF | -11.6 | -20.7 | -14.2 | -8.4 | -15.2 | -7.5 | -0.0 | -35.2 | · | |
| Earnings Yield | -10.6% | -7.2% | -10.4% | -17.2% | -9.9% | -17.2% | · | · | · |
Laporan Laba Rugi 15
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25M | $11M | $6M | $143.0K | $1M | $361.0K | $0 | $0 | $399.0K | $640.0K | $0 | $346.0K | $988.0K | $3M | $709.0K | $458.0K | |
| Cost of Revenue | $154.0K | $200.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| R&D Expense | $100M | $100M | $85M | $90M | $80M | $76M | $67M | $62M | $58M | $53M | $46M | $44M | $41M | $38M | $37M | $32M | |
| SG&A Expense | $58M | $51M | $54M | $52M | $50M | $36M | $28M | $26M | $25M | $21M | $17M | $15M | $13M | $12M | $11M | $12M | |
| Operating Expenses | $158M | $151M | $140M | $143M | $130M | $112M | $95M | $88M | $83M | $74M | $63M | $59M | $54M | $51M | $48M | $44M | |
| Operating Income | $-132M | $-140M | $-134M | $-143M | $-129M | $-111M | $-95M | $-88M | $-83M | $-74M | $-63M | $-59M | $-53M | $-48M | $-48M | $-43M | |
| Interest Income | $12M | $13M | $11M | $13M | $13M | $15M | $14M | $11M | $9M | $7M | $7M | $3M | $2M | $2M | $2M | $2M | |
| Other Non-op | $-423.0K | $-131.0K | $-28M | $-49.0K | $20.0K | $-203.0K | $-16M | $-37.0K | $9M | $7M | $-7M | $3M | $2M | $2M | $3M | $2M | |
| Pretax Income | · | · | $-123M | $-130M | · | · | $-81M | $-77M | · | · | · | · | · | · | · | · | |
| Net Income | $-121M | $-128M | $-123M | $-130M | $-116M | $-97M | $-81M | $-77M | $-74M | $-67M | $-60M | $-57M | $-51M | $-46M | $-45M | $-42M | |
| EPS (Basic) | $-1.14 | $-1.23 | $-1.30 | $-1.38 | $-1.23 | $-1.04 | $-0.86 | $-0.96 | $-0.94 | $-0.93 | $-0.89 | $-1.01 | $-0.94 | $-0.85 | $-0.83 | $-0.78 | |
| EPS (Diluted) | $-1.14 | $-1.23 | $-1.30 | $-1.38 | $-1.23 | $-1.04 | $-0.86 | $-0.96 | $-0.94 | $-0.93 | $-0.89 | $-1.01 | $-0.94 | $-0.85 | $-0.83 | $-0.78 | |
| Shares (Basic) | 105,560,000 | 104,099,000 | -187,051,000 | 94,215,000 | 93,791,000 | 93,102,000 | -150,605,000 | 80,091,000 | 79,008,000 | 72,289,000 | -106,920,000 | 56,808,000 | 54,275,000 | 53,908,000 | -102,020,000 | 53,768,000 | |
| Shares (Diluted) | 105,560,000 | 104,099,000 | -187,051,000 | 94,215,000 | 93,791,000 | 93,102,000 | -150,605,000 | 80,091,000 | 79,008,000 | 72,289,000 | -106,920,000 | 56,808,000 | 54,275,000 | 53,908,000 | -102,020,000 | 53,768,000 | |
| EBITDA | $-132M | $-140M | · | $-143M | $-129M | $-111M | · | $-88M | $-83M | $-74M | · | $-59M | $-53M | $-48M | · | $-43M |
Neraca 23
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $55M | $114M | $102M | $111M | $54M | $95M | $265M | $317M | $302M | $396M | $55M | $143M | $40M | $41M | $33M | $31M | |
| Short-term Investments | $1.15B | $1.18B | $926M | $981M | $1.14B | $1.18B | $1.09B | $545M | $561M | $505M | · | $412M | $225M | $255M | · | $337M | |
| Receivables | $12M | $6M | $592.0K | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Inventory | $3M | $3M | $2M | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $23M | $22M | $18M | $28M | $20M | $16M | $21M | $15M | $12M | $16M | · | $21M | $20M | $9M | · | $10M | |
| Other Current Assets | $5M | $6M | $3M | $5M | $4M | $3M | $2M | $1M | $2M | $4M | · | $4M | $3M | $3M | · | $2M | |
| Current Assets | $1.24B | $1.32B | $1.05B | $1.12B | $1.22B | $1.29B | $1.38B | $878M | $875M | $917M | · | $576M | $285M | $305M | · | $378M | |
| PP&E (Net) | $13M | $13M | $14M | $14M | $15M | $13M | $12M | $12M | $12M | $12M | · | $10M | $3M | $3M | · | $4M | |
| PP&E (Gross) | $23M | $23M | $22M | $21M | $24M | $21M | $20M | $19M | $18M | $17M | · | $15M | $8M | $8M | · | $7M | |
| Accum. Depreciation | $10M | $9M | $8M | $7M | $10M | $9M | $8M | $7M | $6M | $5M | · | $5M | $5M | $4M | · | $4M | |
| Other Non-current Assets | · | · | · | · | · | $14M | · | $3M | $2M | $2M | · | $2M | $2M | $2M | · | · | |
| Total Assets | $1.32B | $1.40B | $1.13B | $1.20B | $1.29B | $1.36B | $1.43B | $937M | $936M | $978M | · | $642M | $293M | $314M | · | $385M | |
| Accounts Payable | $13M | $13M | $23M | $6M | $11M | $10M | $6M | $5M | $9M | $11M | · | $6M | $5M | $6M | · | $6M | |
| Current Liabilities | $80M | $71M | $85M | $74M | $68M | $57M | $60M | $54M | $54M | $52M | · | $40M | $33M | $26M | · | $25M | |
| Capital Leases | $41M | $41M | $42M | $43M | $43M | $44M | $45M | $45M | $46M | $47M | · | $48M | $1M | $2M | · | $2M | |
| Other Non-current Liabilities | $6M | $5M | $3M | $3M | $2M | $2M | $829.0K | $511.0K | $202.0K | · | · | · | · | · | · | · | |
| Total Liabilities | $130M | $121M | $134M | $124M | $118M | $107M | $110M | $104M | $105M | $103M | · | $94M | $39M | $34M | · | $34M | |
| Common Stock | · | · | · | · | · | · | · | · | · | $881.0K | · | · | · | · | · | · | |
| Retained Earnings | $-1.67B | $-1.55B | $-1.42B | $-1.29B | $-1.16B | $-1.05B | $-952M | $-872M | $-795M | $-721M | · | $-594M | $-536M | $-485M | · | $-394M | |
| AOCI | $-3M | $-1M | $2M | $2M | $2M | $2M | $963.0K | $2M | $-190.0K | $150.0K | · | $-865.0K | $-2M | $-3M | · | $-5M | |
| Stockholders' Equity | $1.19B | $1.28B | $992M | $1.07B | $1.17B | $1.25B | $1.32B | $833M | $831M | $875M | $539M | $548M | $254M | $280M | $316M | $351M | |
| Liabilities + Equity | $1.32B | $1.40B | $1.13B | $1.20B | $1.29B | $1.36B | $1.43B | $937M | $936M | $978M | · | $642M | $293M | $314M | · | $385M | |
| Shares Outstanding | 105,808,000 | 105,314,000 | 95,575,000 | 94,548,000 | 94,126,000 | 93,525,000 | 92,926,000 | 80,841,000 | 79,322,000 | 78,539,000 | · | 66,708,000 | 54,682,000 | 53,990,000 | · | 53,796,000 |
Arus Kas 10
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $994.0K | $1M | $959.0K | $925.0K | $788.0K | $770.0K | $753.0K | $474.0K | $262.0K | $273.0K | $280.0K | $283.0K | $280.0K | $248.0K | |
| Stock-based Comp | $25M | $30M | $22M | $23M | $26M | $20M | $19M | $18M | $19M | $13M | $12M | $11M | $10M | $8M | $8M | $7M | |
| Operating Cash Flow | $-94M | $-125M | $-93M | $-111M | $-86M | $-88M | $-67M | $-65M | $-48M | $-53M | $-41M | $-41M | $-46M | $-41M | $-35M | $-38M | |
| CapEx | $521.0K | $820.0K | $458.0K | $863.0K | $3M | $1M | $1M | $528.0K | $955.0K | $1M | $935.0K | $4M | $237.0K | $16.0K | $274.0K | $682.0K | |
| Investing Cash Flow | $26M | $-252M | $57M | $165M | $38M | $-86M | $-542M | $21M | $-54M | $309.0K | $-87M | $-193M | $31M | $49M | $37M | $7M | |
| Stock Issued | $0 | $381M | $0 | $0 | $0 | $0 | $544M | $63M | $10M | $383M | $29M | $329M | $11M | $0 | $0 | $-13.0K | |
| Net Stock Activity | · | $381M | · | · | · | $0 | · | · | · | $383M | · | · | · | · | · | · | |
| Financing Cash Flow | $9M | $390M | $26M | $3M | $7M | $4M | $556M | $59M | $8M | $394M | $40M | $338M | $13M | $484.0K | $115.0K | $1M | |
| Net Change in Cash | · | · | · | $57M | $-41M | $-170M | · | $15M | $-94M | $341M | · | $103M | $-2M | $9M | $2M | $-31M | |
| Free Cash Flow | · | $-126M | · | · | · | $-90M | · | · | · | $-54M | · | · | · | $-41M | · | · |
Profitabilitas 6
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -527.4% | -1307.8% | · | -99710.5% | -12523.0% | -30860.1% | · | · | -20747.6% | -11488.9% | · | -17045.4% | -5363.9% | -1790.9% | · | -9487.8% | |
| Net Margin | -481.1% | -1191.0% | · | -90972.7% | -11216.0% | -26807.2% | · | · | -18560.1% | -10457.8% | · | -16606.4% | -5159.8% | -1716.9% | · | -9153.9% | |
| Pretax Margin | · | · | · | -90972.7% | · | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -527.4% | -1307.8% | · | -99710.5% | -12523.0% | -30860.1% | · | · | -20747.6% | -11488.9% | · | -17045.4% | -5363.9% | -1790.9% | · | -9487.8% | |
| ROA | -9.3% | -9.3% | · | -12.2% | -10.4% | -8.3% | · | -9.7% | -12.0% | -10.4% | · | -11.2% | -14.3% | -14.2% | · | -14.1% | |
| ROE | -10.2% | -10.1% | · | -13.7% | -11.6% | -9.1% | · | -11.1% | -13.7% | -11.6% | · | -12.8% | -15.9% | -15.8% | · | -15.4% |
Likuiditas & Solvabilitas 2
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.6 | 18.6 | · | 15.1 | 17.8 | 22.5 | · | 16.4 | 16.1 | 17.7 | · | 14.2 | 8.7 | 11.6 | · | 15.4 | |
| Quick Ratio | 15.2 | 18.2 | · | 14.7 | 17.5 | 22.2 | · | 16.1 | 15.9 | 17.4 | · | 13.7 | 8.1 | 11.3 | · | 15.0 |
Efisiensi 3
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.1 | 0.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 4.2 | 3.8 | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Valuasi (TTM) 10
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $37M | $12M | · | $2M | $2M | $1M | · | $1M | $2M | $5M | · | $4M | $5M | $7M | · | $4M | |
| Net Income TTM | $-494M | $-470M | · | $-419M | $-363M | $-315M | · | $-275M | $-249M | $-221M | · | $-196M | $-181M | $-165M | · | $-147M | |
| Market Cap | $3.96B | $3.83B | · | $3.94B | $2.71B | $3.14B | · | $4.13B | $3.55B | $3.68B | · | $1.98B | $985M | $867M | · | $1.06B | |
| P/E | -7.5 | -7.4 | · | -9.0 | -6.9 | -8.7 | · | -13.3 | -11.7 | -12.5 | · | -8.3 | -5.3 | -5.1 | · | -6.4 | |
| P/S | 106.9 | 311.8 | · | 2565.4 | 1511.5 | 2240.6 | · | 2982.7 | 1497.2 | 790.1 | · | 443.7 | 215.9 | 129.3 | · | 262.3 | |
| P/B | 3.3 | 3.0 | · | 3.7 | 2.3 | 2.5 | · | 5.0 | 4.3 | 4.2 | · | 3.6 | 3.9 | 3.1 | · | 3.0 | |
| P / Tangible Book | 3.3 | 3.0 | · | 3.7 | 2.3 | 2.5 | · | 5.0 | 4.3 | 4.2 | · | 3.6 | 3.9 | 3.1 | · | 3.0 | |
| P / Cash Flow | · | -30.7 | · | · | · | -35.5 | · | · | · | -69.6 | · | · | · | -21.3 | · | · | |
| P / FCF | · | -30.5 | · | · | · | -35.0 | · | · | · | -67.8 | · | · | · | -21.3 | · | · | |
| Earnings Yield | -13.3% | -13.4% | · | -11.1% | -14.5% | -11.5% | · | -7.5% | -8.5% | -8.0% | · | -12.0% | -18.8% | -19.7% | · | -15.5% |
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
Laporan Laba Rugi
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Pendapatan | $8M | $1M | $4M | $5M | $1M |
| Margin Operasi % | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% |
| Laba Bersih | $-465M | $-298M | $-215M | $-164M | $-108M |
| EPS Dilusian | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 |
Neraca
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Rasio Lancar | 12.3 | 23.0 | 13.1 | 12.5 | 21.6 |
| Rasio Cepat | 12.1 | 22.7 | 12.7 | 12.1 | 20.9 |
Arus Kas
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Arus Kas Bebas | $-384M | $-230M | $-171M | $-117M | $-89M |
Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini
- Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal
- Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
- Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
- Why This Pharmaceutical Stock Jumped Close to 100% This Week
- Crinetics Pharmaceuticals (CRNX) is One of the Best AI Driven Biotech Stocks, Here is Why
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
📊
Pilih metrik yang penting bagi Anda — klik ➕ di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Pemilik institusional (13F) 287 pengaju · $3.2B total · Per tanggal 30 Juni 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 63 (+17 vs Kuartal sebelumnya) | 30 (-14 vs Kuartal sebelumnya) | 95 (-17 vs Kuartal sebelumnya) | 63 (+3 vs Kuartal sebelumnya) | +21.6M |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| FMR LLC | $486.250.673 | 12.994.406 | 15,13% | Saham |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $336.372.047 | 8.989.098 | 10,46% | Saham |
| Driehaus Capital Management LLC | $241.866.078 | 6.463.551 | 7,52% | Saham |
| WELLINGTON MANAGEMENT GROUP LLP | $237.002.526 | 6.333.579 | 7,37% | Saham |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $180.836.416 | 4.832.614 | 5,63% | Saham |
| VANGUARD CAPITAL MANAGEMENT LLC | $177.567.704 | 4.745.262 | 5,52% | Saham |
| STATE STREET CORP | $100.635.477 | 2.689.350 | 3,13% | Saham |
| Bellevue Group AG | $98.040.400 | 2.620.000 | 3,05% | Saham |
| BAKER BROS. ADVISORS LP | $87.991.820 | 2.351.465 | 2,74% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $87.542.675 | 2.338.905 | 2,72% | Saham |
| Polar Capital Holdings Plc | $85.108.460 | 2.274.411 | 2,65% | Saham |
| Pictet Asset Management Holding SA | $77.572.984 | 2.075.375 | 2,41% | Saham |
| Siren, L.L.C. | $53.165.887 | 1.420.788 | 1,65% | Saham |
| First Light Asset Management, LLC | $50.923.606 | 1.360.866 | 1,58% | Saham |
| NOVO HOLDINGS A/S | $49.394.400 | 1.320.000 | 1,54% | Saham |
| AMERICAN CENTURY COMPANIES INC | $47.245.129 | 1.262.562 | 1,47% | Saham |
| ADAR1 Capital Management, LLC | $45.730.234 | 1.222.080 | 1,42% | Saham |
| DIMENSIONAL FUND ADVISORS LP | $44.555.208 | 1.190.679 | 1,39% | Saham |
| MONTANOVA CAPITAL, LLC | $44.390.560 | 1.186.279 | 1,38% | Saham |
| ORBIMED ADVISORS LLC | $37.382.580 | 999.000 | 1,16% | Saham |
| Hood River Capital Management LLC | $36.259.830 | 968.996 | 1,13% | Saham |
| GOLDMAN SACHS GROUP INC | $34.657.132 | 926.166 | 1,08% | Saham |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $32.841.401 | 877.643 | 1,02% | Saham |
| Aberdeen Group plc | $30.699.181 | 820.395 | 0,95% | Saham |
| Candriam S.C.A. | $30.618.690 | 819.032 | 0,95% | Saham |
| VANGUARD FIDUCIARY TRUST CO | $28.230.995 | 754.436 | 0,88% | Saham |
| Fisher Asset Management, LLC | $27.748.912 | 741.553 | 0,86% | Saham |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $17.709.036 | 479.400 | 0,55% | Saham |
| AMERIPRISE FINANCIAL INC | $17.451.149 | 466.356 | 0,54% | Saham |
| Impax Asset Management Group plc | $16.277.700 | 435.000 | 0,51% | Saham |
| Prosight Management, LP | $14.020.002 | 374.666 | 0,44% | Saham |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $13.991.714 | 373.910 | 0,44% | Saham |
| KENNEDY CAPITAL MANAGEMENT LLC | $13.685.018 | 365.714 | 0,43% | Saham |
| BRAUN STACEY ASSOCIATES INC | $13.027.511 | 348.143 | 0,41% | Saham |
| Fiera Capital Corp | $12.395.263 | 331.247 | 0,39% | Saham |
| BANK OF AMERICA CORP /DE/ | $11.271.877 | 301.226 | 0,35% | Saham |
| Defilade Capital Management, L.P. | $8.959.845 | 239.440 | 0,28% | Saham |
| SEB Asset Management AB | $8.003.786 | 213.891 | 0,25% | Saham |
| Foresite Capital Management VI LLC | $7.933.414 | 212.010 | 0,25% | Saham |
| RICE HALL JAMES & ASSOCIATES, LLC | $7.346.220 | 196.318 | 0,23% | Saham |
| TD Asset Management Inc | $7.152.534 | 191.142 | 0,22% | Saham |
| Swiss National Bank | $6.877.796 | 183.800 | 0,21% | Saham |
| SEGALL BRYANT & HAMILL, LLC | $6.855.307 | 183.199 | 0,21% | Saham |
| BlackRock, Inc. | $6.781.290 | 181.221 | 0,21% | Saham |
| JENNISON ASSOCIATES LLC | $6.056.839 | 161.861 | 0,19% | Saham |
| New Leaf Venture Partners, L.L.C. | $5.872.650 | 141.000 | 0,18% | Saham |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $5.865.136 | 156.738 | 0,18% | Saham |
| Foresite Capital Management IV, LLC | $5.613.000 | 150.000 | 0,17% | Saham |
| Bank of New York Mellon Corp | $5.581.754 | 149.165 | 0,17% | Saham |
| NEW YORK STATE COMMON RETIREMENT FUND | $5.508.898 | 147.218 | 0,17% | Saham |
| ENVESTNET ASSET MANAGEMENT INC | $5.471.384 | 146.216 | 0,17% | Saham |
| Moody Aldrich Partners LLC | $5.466.201 | 146.077 | 0,17% | Saham |
| Ishara Investments LP | $5.369.770 | 143.500 | 0,17% | Saham |
| CITADEL ADVISORS LLC | $5.176.271 | 138.329 | 0,16% | Saham |
| RHUMBLINE ADVISERS | $4.861.141 | 129.908 | 0,15% | Saham |
| ALLIANCEBERNSTEIN L.P. | $4.782.618 | 131.680 | 0,15% | Saham |
| GordonMD Global Investments LP | $4.751.779 | 126.985 | 0,15% | Saham |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $4.712.974 | 125.948 | 0,15% | Saham |
| JANUS HENDERSON GROUP PLC | $4.700.428 | 129.392 | 0,15% | Saham |
| Cormorant Asset Management, LP | $4.677.500 | 125.000 | 0,15% | Saham |
| SECTOR GAMMA AS | $4.289.380 | 114.628 | 0,13% | Saham |
| XTX Topco Ltd | $4.164.547 | 111.292 | 0,13% | Saham |
| ALPS ADVISORS INC | $3.981.825 | 106.409 | 0,12% | Saham |
| FEDERATED HERMES, INC. | $3.957.390 | 105.756 | 0,12% | Saham |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $3.834.048 | 105.563 | 0,12% | Saham |
| Nuveen Asset Management, LLC | $3.760.151 | 73.541 | 0,12% | Saham |
| Burkehill Global Management, LP | $3.742.000 | 100.000 | 0,12% | Saham |
| Nuveen, LLC | $3.619.262 | 96.720 | 0,11% | Saham |
| VICTORY CAPITAL MANAGEMENT INC | $3.484.251 | 93.112 | 0,11% | Saham |
| MORGAN STANLEY | $3.320.829 | 88.744 | 0,10% | Saham |
| TWO SIGMA INVESTMENTS, LP | $3.266.729 | 87.299 | 0,10% | Saham |
| VANGUARD ASSET MANAGEMENT, Ltd | $3.254.754 | 86.979 | 0,10% | Saham |
| AWM Investment Company, Inc. | $3.180.700 | 85.000 | 0,10% | Saham |
| Odyssean, LLC | $3.160.344 | 84.456 | 0,10% | Saham |
| Affinity Asset Advisors, LLC | $2.806.500 | 75.000 | 0,09% | Saham |
| ALGERT GLOBAL LLC | $2.714.147 | 72.532 | 0,08% | Saham |
| ExodusPoint Capital Management, LP | $2.652.404 | 70.882 | 0,08% | Saham |
| Ensign Peak Advisors, Inc | $2.507.290 | 67.004 | 0,08% | Saham |
| BARCLAYS PLC | $2.466.127 | 65.904 | 0,08% | Saham |
| FIRST TRUST ADVISORS LP | $2.370.631 | 63.352 | 0,07% | Saham |
| Man Group plc | $2.284.229 | 61.043 | 0,07% | Saham |
| MetLife Investment Management, LLC | $2.258.709 | 60.361 | 0,07% | Saham |
| CITIGROUP INC | $2.255.229 | 60.268 | 0,07% | Saham |
| Longaeva Partners L.P. | $2.184.879 | 58.388 | 0,07% | Saham |
| Swedbank AB | $2.155.392 | 57.600 | 0,07% | Saham |
| STATE OF WISCONSIN INVESTMENT BOARD | $2.068.016 | 55.265 | 0,06% | Saham |
| Jump Financial, LLC | $1.923.388 | 51.400 | 0,06% | Saham |
| Lighthouse Investment Partners, LLC | $1.871.000 | 50.000 | 0,06% | Saham |
| Vestmark Advisory Solutions, Inc. | $1.823.252 | 48.724 | 0,06% | Saham |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $1.787.254 | 47.762 | 0,06% | Saham |
| VANGUARD GROUP INC | $1.774.626 | 38.123 | 0,06% | Saham |
| Point72 Asset Management, L.P. | $1.735.577 | 46.381 | 0,05% | Saham |
| BNP PARIBAS FINANCIAL MARKETS | $1.696.398 | 45.334 | 0,05% | Saham |
| RAYMOND JAMES FINANCIAL INC | $1.606.254 | 42.925 | 0,05% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.549.188 | 41.400 | 0,05% | Opsi beli |
| Invesco Ltd. | $1.545.446 | 41.300 | 0,05% | Saham |
| Vanguard Global Advisers, LLC | $1.485.986 | 39.711 | 0,05% | Saham |
| HighMark Wealth Management LLC | $1.444.224 | 38.595 | 0,04% | Saham |
| OAK RIDGE INVESTMENTS LLC | $1.405.046 | 37.548 | 0,04% | Saham |
| Orion Porfolio Solutions, LLC | $1.404.234 | 37.526 | 0,04% | Saham |
Orang dalam perusahaan 20 orang dalam · 9 pejabat · 10 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Tobin Schilke | Chief Financial Officer | 10 Maret 2025 A | 52.000 | 0 | 0 | $0 |
| Marc Wilson | CFO | 26 Sep. 2024 M | 111.092 | 0 | 0 | $0 |
| Jeff E. Knight | Chief Operating Officer | 19 Maret 2025 S | 87.491 | 0 | 0 | $0 |
| Stephen F. Betz | Chief Scientific Officer | 12 Juni 2025 M | 99.713 | 0 | 0 | $0 |
| Dana Pizzuti | Chief Med and Dev Officer | 19 Maret 2025 S | 72.233 | 0 | 0 | $0 |
| Isabel Kalofonos | Chief Commercial Officer | 10 Jan. 2025 A | — | 0 | 0 | $0 |
| James Hassard | Chief Commercial Officer | 5 Juli 2024 M | 29.259 | 0 | 0 | $0 |
| Alan Seth Krasner | Chief Medical Officer | 17 Okt. 2023 M | 43.210 | 0 | 0 | $0 |
| Ajay Madan | Chief Development Officer | 28 Feb. 2022 A | 176.995 | 0 | 0 | $0 |
| Coelho Rogerio Vivaldi | Direktur | 2 Juli 2026 S | 19.225 | 0 | 1 | $-120.000 |
| Caren Deardorf | Direktur | 18 Juni 2026 A | 22.225 | 0 | 0 | $0 |
| Weston Nichols | Direktur | 18 Juni 2026 A | 22.225 | 0 | 0 | $0 |
| Stephanie Okey | Direktur | 18 Juni 2026 A | 12.325 | 0 | 2 | $-246.143 |
| Matthew K Fust | Direktur | 18 Juni 2026 A | 28.761 | 0 | 0 | $0 |
| Camille L Bedrosian | Direktur | 18 Juni 2026 A | 22.225 | 0 | 0 | $0 |
| Wendell Wierenga | Direktur | 18 Juni 2026 A | 122.071 | 0 | 0 | $0 |
| Wendall Wierenga | Direktur | 11 Juni 2025 A | 116.146 | 0 | 0 | $0 |
| Stephen W Kaldor | Direktur | 19 Juni 2020 A | — | 0 | 0 | $0 |
| Jack Nielsen | Direktur | 21 Juni 2019 A | — | 0 | 0 | $0 |
| Richard Scott Struthers | — | 7 Agu 2026 M | 424.706 | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Aktivis & pemilik 5%+ 1 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| Perceptive Advisors LLC, Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd. ×6 pengajuan | 1 Maret 2024 | — | Pengajuan awal | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Kepemilikan ETF Dimiliki oleh 55 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| SBIO · ALPS ETF Trust | 2,37% | 107.892 NS | 31 Mei 2026 | N-PORT |
| IHE · iShares Trust | 1,95% | 376.636 SH | 8 Agu 2026 | Harian |
| FMED · Fidelity Covington Trust | 1,65% | 19.000 NS | 31 Mei 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 1,40% | 4.666 NS | 30 April 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,23% | 18.743 NS | 30 April 2026 | N-PORT |
| MMSC · First Trust Exchange-Traded Fund VI… | 0,75% | 11.043 NS | 31 Mei 2026 | N-PORT |
| IBB · iShares Trust | 0,63% | 718.323 SH | 8 Agu 2026 | Harian |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,60% | 5.737 SH | 8 Agu 2026 | Harian |
| IWO · iShares Trust | 0,54% | 940.202 SH | 8 Agu 2026 | Harian |
| NUSC · Nushares ETF Trust | 0,28% | 93.045 NS | 30 April 2026 | N-PORT |
| ISCG · iShares Trust | 0,27% | 32.694 SH | 8 Agu 2026 | Harian |
| IWM · iShares Trust | 0,27% | 2.625.192 SH | 8 Agu 2026 | Harian |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,23% | 110.770 SH | 8 Agu 2026 | Harian |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,20% | 38.553 NS | 30 April 2026 | N-PORT |
| BIB · ProShares Trust | 0,19% | 3.872 NS | 31 Mei 2026 | N-PORT |
| ESML · iShares Trust | 0,16% | 55.438 SH | 8 Agu 2026 | Harian |
| BKSE · BNY Mellon ETF Trust | 0,15% | 3.142 NS | 30 April 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,15% | 51.135 SH | 8 Agu 2026 | Harian |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,14% | 18.879 NS | 30 April 2026 | N-PORT |
| ISCB · iShares Trust | 0,13% | 4.625 SH | 8 Agu 2026 | Harian |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,12% | 596.648 SH | 8 Agu 2026 | Harian |
| RSSL · Global X Funds | 0,12% | 42.391 NS | 30 April 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,11% | 1.399.667 SH | 8 Agu 2026 | Harian |
| FFSM · FIDELITY COVINGTON TRUST | 0,10% | 31.759 NS | 30 April 2026 | N-PORT |
| ITWO · ProShares Trust | 0,09% | 4.601 NS | 31 Mei 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,09% | 2.909 SH | 8 Agu 2026 | Harian |
| SCHA · SCHWAB STRATEGIC TRUST | 0,08% | 492.431 NS | 31 Mei 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,07% | 24.991 NS | 30 April 2026 | N-PORT |
| WSML · iShares Trust | 0,07% | 5.742 SH | 8 Agu 2026 | Harian |
| FHLC · FIDELITY COVINGTON TRUST | 0,06% | 41.183 NS | 30 April 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,05% | 196.549 NS | 30 April 2026 | N-PORT |
| UWM · ProShares Trust | 0,05% | 3.599 NS | 31 Mei 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,05% | 2.419.186 SH | 8 Agu 2026 | Harian |
| VHT · VANGUARD WORLD FUND | 0,05% | 275.155 SH | 8 Agu 2026 | Harian |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,04% | 5.196 NS | 30 April 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,04% | 1.210.574 SH | 8 Agu 2026 | Harian |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,04% | 112 NS | 31 Mei 2026 | N-PORT |
| URTY · ProShares Trust | 0,04% | 3.643 NS | 31 Mei 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,02% | 5.689 NS | 31 Mei 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,02% | 3.773 NS | 31 Mei 2026 | N-PORT |
| HDG · ProShares Trust | 0,02% | 91 NS | 31 Mei 2026 | N-PORT |
| ITOT · iShares Trust | 0,01% | 146.419 SH | 8 Agu 2026 | Harian |
| IWV · iShares Trust | 0,01% | 27.043 SH | 8 Agu 2026 | Harian |
| DFAC · Dimensional ETF Trust | 0,01% | 125.853 NS | 30 April 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,01% | 3.342.704 SH | 8 Agu 2026 | Harian |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 8.345 SH | 8 Agu 2026 | Harian |
| ESGV · VANGUARD WORLD FUND | 0,01% | 22.843 SH | 8 Agu 2026 | Harian |
| ONEQ · Fidelity Commonwealth Trust | 0,01% | 28.694 NS | 31 Mei 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,01% | 5.863 NS | 30 April 2026 | N-PORT |
| TILT · FlexShares Trust | 0,01% | 3.388 NS | 30 April 2026 | N-PORT |